Bright Minds Biosciences (DRUG) Price & Analysis

Compare

66 Followers

DRUG Stock Chart & Stats

Day’s Range― - ―

52-Week RangeC$1.35 - C$108.00

Previous CloseN/A

Volume70.00

Average Volume (3M)467.00

Market Cap

C$432.16M

Enterprise ValueC$204.27M

Total Cash (Recent Filing)C$51.39M

Total Debt (Recent Filing)C$141.03K

Price to Earnings (P/E)―

Beta24.45

Next Earnings

Dec 18, 2025

EPS Estimate

-0.95

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.74

Shares Outstanding7,084,639

10 Day Avg. Volume320

30 Day Avg. Volume467

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$117.58

Price Target Upside92.75% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical TrialsBright Minds Biosciences is advancing toward a key catalyst with top-line data from the Phase 2 BREAKTHROUGH trial evaluating BMB-101 in absence epilepsy and developmental and epileptic encephalopathies (DEE).

Financial StabilityBright Minds is well-capitalized with approximately C$51 million in cash, providing a runway into 2027.

Market OpportunityPositive data could position BMB-101 as a best-in-class therapy in both DEE and absence epilepsy, addressing a combined refractory market opportunity estimated at $21 billion.

Bears Say

CompetitionThe data have a high bar due to the potent anti-seizure activity shown by competitive 5-HT2C agonists in certain DEE populations.

Regulatory And Clinical RisksThe Phase 2 BREAKTHROUGH program is advancing toward a readout in both absence epilepsy and developmental and epileptic encephalopathies, indicating strong potential to unlock value across a large, underserved treatment-resistant epilepsy market.

Bright Minds Biosciences News

Psychedelic: Bright Minds reports preclinical BMB-201 results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

4d ago

CMPS

CYBN

Bright Minds says BMB-201 outperforms sumatriptan in preclinical model

Bright Minds (DRUG) Biosciences announced preclinical results for its investigational compound BMB-201, in a validated isosorbide dinitrate rat...

4d ago

DRUG

Psychedelic: atai Life Sciences, Cybin report earnings results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

25d ago

ATAI

CYBN

Bright Minds Biosciences Launches $100 Million At-The-Market Offering

Bright Minds Biosciences ( ($TSE:DRUG) ) has provided an update. Bright Minds Biosciences announced an at-the-market equity offering...

3d ago

DRUG

Bright Minds Biosciences: Advancing Breakthrough Epilepsy Treatment with BMB-101 and Strong Financial Position

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Bright Minds Biosciences, retaining the price target...

20d ago

DRUG

Bright Minds Biosciences Reports Q3 2025 Financial Results

Bright Minds Biosciences ( ($TSE:DRUG) ) has shared an announcement. Bright Minds Biosciences Inc. has released its Condensed...

24d ago

DRUG

Psychedelic: atai Life Sciences, Beckley Psytech report BPL-003 study results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

2M ago

ATAI

CMND

Bright Minds assumed with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage of Bright Minds (DRUG) with an Overweight rating and no price target Bright Minds’...

2M ago

DRUG

Bright Minds Biosciences to Present at 2025 Jefferies Global Healthcare Conference

Bright Minds Biosciences ( ($TSE:DRUG) ) has provided an announcement. Bright Minds Biosciences announced that its CEO and...

3M ago

DRUG

Bright Minds Biosciences’ BMB-101: A Promising Breakthrough in Treatment-Resistant Epilepsy

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Bright Minds Biosciences...

4M ago

DRUG

Bright Minds Biosciences: Buy Rating Issued on Promising Potential of BMB-101 for Absence Seizures

TD Cowen analyst Joseph Thome has maintained their bullish stance on DRUG stock, giving a Buy rating on...

4M ago

DRUG

Bright Minds Biosciences Hosts Virtual R&D Day on Absence Epilepsy

Bright Minds Biosciences ( ($TSE:DRUG) ) has provided an update. Bright Minds Biosciences announced the featured speakers for...

4M ago

DRUG

Bright Minds announces speakers for Absence epilepsy R&D Day

Bright Minds (DRUG) Biosciences announced the featured speakers for its virtual R&D Day on Tuesday, May 20, 2025,...

4M ago

DRUG

VA secretary wants to find answers on psychedelics therapies, Politico says

Veterans Affairs Secretary Doug Collins wants to find out whether psychedelic drugs can successfully treat veterans with PTSD...

4M ago

ATAI

CYBN

DRUG FAQ

What was Bright Minds Biosciences’s price range in the past 12 months?

Bright Minds Biosciences lowest stock price was C$1.35 and its highest was C$108.00 in the past 12 months.

What is Bright Minds Biosciences’s market cap?

Bright Minds Biosciences’s market cap is C$432.16M.

When is Bright Minds Biosciences’s upcoming earnings report date?

Bright Minds Biosciences’s upcoming earnings report date is Dec 18, 2025 which is in 101 days.

How were Bright Minds Biosciences’s earnings last quarter?

Bright Minds Biosciences released its earnings results on Aug 14, 2025. The company reported -C$0.74 earnings per share for the quarter, beating the consensus estimate of -C$0.794 by C$0.054.

Is Bright Minds Biosciences overvalued?

According to Wall Street analysts Bright Minds Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bright Minds Biosciences pay dividends?

Bright Minds Biosciences does not currently pay dividends.

What is Bright Minds Biosciences’s EPS estimate?

Bright Minds Biosciences’s EPS estimate is -0.95.

How many shares outstanding does Bright Minds Biosciences have?

Bright Minds Biosciences has 7,084,639 shares outstanding.

What happened to Bright Minds Biosciences’s price movement after its last earnings report?

Bright Minds Biosciences reported an EPS of -C$0.74 in its last earnings report, beating expectations of -C$0.794. Following the earnings report the stock price went up 8.324%.

Which hedge fund is a major shareholder of Bright Minds Biosciences?

Currently, no hedge funds are holding shares in TSE:DRUG

Bright Minds Biosciences Stock Smart Score

Underperform

Fundamentals

Return on Equity

-30.79%

Trailing 12-Months

Asset Growth

736.23%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bright Minds Biosciences

Bright Minds Biosciences (DRUG) is a biotechnology company focused on developing novel psychedelic and serotonergic compounds for the treatment of neuropsychiatric disorders, epilepsy, and other central nervous system (CNS) related conditions. Leveraging cutting-edge science and research, the company's core mission is to address unmet medical needs in mental health through innovation and advanced drug development.

Bright Minds Biosciences (DRUG) Earnings & Revenues

Historic Earnings Reports

DRUG Stock 12 Month Forecast

Average Price Target

C$117.58

▲(92.75% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"C$0","59":"C$59","118":"C$118","29.5":"C$29.5","88.5":"C$88.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":117.58472705,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$117.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":117.58,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$117.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":117.58472705,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$117.58</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,29.5,59,88.5,118],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.69,50.29728669615385,55.90457339230769,61.51186008846153,67.11914678461538,72.72643348076923,78.33372017692307,83.94100687307692,89.54829356923076,95.15558026538461,100.76286696153846,106.3701536576923,111.97744035384615,{"y":117.58472705,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.69,50.29692307692307,55.90384615384615,61.51076923076923,67.11769230769231,72.72461538461539,78.33153846153846,83.93846153846154,89.54538461538462,95.15230769230769,100.75923076923077,106.36615384615385,111.97307692307692,{"y":117.58,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.69,50.29728669615385,55.90457339230769,61.51186008846153,67.11914678461538,72.72643348076923,78.33372017692307,83.94100687307692,89.54829356923076,95.15558026538461,100.76286696153846,106.3701536576923,111.97744035384615,{"y":117.58472705,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.45,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.3,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.47,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":67.15,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":67.15,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.59,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.98,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.11,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.03,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >